Should I Buy ALXO? ALXO 2026 Analysis

Should You Buy ALX Oncology Holdings Inc (ALXO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.500

1 Day change

9.49%

52 Week Range

2.270

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner long-term investor who’s impatient. Despite a short-term technical upswing, ALXO is a pre-revenue biotech with widening losses (2025/Q3) and options flow skewed bearish (put-heavy volume). With no near-term news catalysts and high volatility, the risk/reward isn’t attractive for your profile at this moment.

Technical Analysis

Pre-market price ~1.485 (around prior close ~1.50). Trend is short-term bullish: MACD histogram is positive and expanding (0.0298), RSI(6) ~64.9 (near upper-neutral, not yet overbought), and moving averages are stacked bullish (SMA_5 > SMA_20 > SMA_200), implying upward momentum. However, price is approaching overhead resistance at R1 ~1.521 (then R2 ~1.615). Key support is pivot ~1.368 (then S1 ~1.215). Pattern-based projection shows near-term strength (next week +5.94%) but weaker 1-month expectation (-7.12%), suggesting the current bounce may fade. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Options sentiment looks cautious-to-bearish near-term: put/call open interest is slightly put-leaning (1.07), while put volume is much heavier than call volume (put-call volume ratio 2.86), which often reflects hedging or bearish speculation. Volatility is extremely high (30D IV ~190% vs historical vol ~129%), but IV rank/percentile are relatively low (IV rank ~9.8; IV percentile ~27.2), implying IV has been even higher recently. Today’s options activity is elevated vs the 30-day average (volume ~10x avg; open interest also elevated), signaling heightened positioning/attention.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical momentum is currently constructive (bullish MA stack, positive/expanding MACD).
- Wall Street coverage is supportive: Jefferies initiated with a Buy and $4 target, highlighting focus on lead programs (Evorpacept and ALX2004).
- Hedge funds and insiders show no significant recent selling pressure (both neutral trends).

Neutral/Negative Catalysts

- No news in the last week: no fresh catalyst to justify chasing the move.
- Options flow is put-volume heavy (bearish/hedging tilt).
- Small-cap biotech profile with very high volatility and uncertain catalyst timing is a poor fit for a beginner long-term investor who doesn’t want to wait for better entries.
- Pattern-based outlook suggests potential weakness over the next month (-7.12% expected move in the pattern study).

Financial Performance

Latest reported quarter: 2025/Q3. Revenue was 0 (no operating revenue; unchanged). Losses widened: net income fell to -$22.144M (more negative, -27.89% YoY) and EPS declined to -0.41 (-29.31% YoY). Overall, the quarter shows continued cash burn without revenue growth, which increases dependence on clinical progress/financing rather than business fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst activity is limited but positive: on 2025-11-13 Jefferies initiated coverage with a Buy and a $4 price target. Pros: focus on two lead programs and differentiated pipeline rationale. Cons: this is initiation-level support rather than broad, repeated upgrades; without new clinical/news catalysts, the stock can remain driven by sentiment, financing risk, and trial timelines. Politicians/congress trades: no recent congress trading data available; influential-figure activity not indicated in the provided data.

4 Analyst Rating

Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3 USD with a low forecast of 2 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.370

Low

Averages

High

Current: 1.370

Low

Averages

High

Jefferies

NULL -> Buy

initiated

AI Analysis

2025-11-13

Reason

Jefferies

Price Target

AI Analysis

2025-11-13

initiated

NULL -> Buy

Reason

Jefferies initiated coverage of ALX Oncology with a Buy rating and $4 price target. ALX has strategically focused on two lead programs, Evorpacept in post-ENHERTU HER2+ mBC using prospective CD47 enrichment, supported by "encouraging" gastric data and ALX2004, an ADC with a differentiated design for wider therapeutic window in solid tumors, the analyst tells investors.

UBS

Buy

downgrade

2025-05-21

Reason

UBS

Price Target

2025-05-21

downgrade

Buy

Reason

UBS lowered the firm's price target on ALX Oncology to $1 from $1.20 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALXO

Unlock Now

ALXO Should I Buy

ALXO Should I Buy

Should You Buy ALX Oncology Holdings Inc (ALXO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch